92 related articles for article (PubMed ID: 25024079)
1. Plasma cell neoplasms, their precursor States, and their prediction of organ damage.
Comenzo RL
J Clin Oncol; 2014 Sep; 32(25):2679-82. PubMed ID: 25024079
[No Abstract] [Full Text] [Related]
2. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.
Girnius S; Seldin DC; Cibeira MT; Sanchorawala V
J Clin Oncol; 2013 Jul; 31(21):2749-50. PubMed ID: 23775968
[No Abstract] [Full Text] [Related]
3. [New possibilities of the diagnosis and monitoring of the course of AL-amyloidosis].
Rameev VV; Kozlovskaia LV; Kogarko IN; Kogarko BS
Ter Arkh; 2010; 82(6):29-32. PubMed ID: 20731106
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal Localized Light Chain Amyloidosis-A Distinct Entity?
Ravindran A; Grogg KL; Domaas DA; Go RS
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):588-592. PubMed ID: 27600986
[No Abstract] [Full Text] [Related]
5. Reply to S. Girnius et al.
Palladini G; Dispenzieri A; Gertz M; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2013 Jul; 31(21):2750-1. PubMed ID: 24040662
[No Abstract] [Full Text] [Related]
6. The challenge of systemic immunoglobulin light-chain amyloidosis (Al).
Palladini G; Comenzo RL
Subcell Biochem; 2012; 65():609-42. PubMed ID: 23225018
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
Morris KL; Tate JR; Gill D; Kennedy G; Wellwood J; Marlton P; Bird R; Mills AK; Mollee P
Intern Med J; 2007 Jul; 37(7):456-63. PubMed ID: 17547724
[TBL] [Abstract][Full Text] [Related]
8. In reply to Tate et al. Clin Chim Acta 2007;376:30-6.
Robson E; Mead G; Carr-Smith H; Bradwell A
Clin Chim Acta; 2007 May; 380(1-2):247; author reply 250-1. PubMed ID: 17368602
[No Abstract] [Full Text] [Related]
9. Cardiac amyloidosis--sustained clinical and free light chain response to low dose thalidomide and corticosteroids.
Campbell P; Murdock C
Intern Med J; 2006 Feb; 36(2):137-9. PubMed ID: 16472271
[No Abstract] [Full Text] [Related]
10. [Determination of light chains in serum].
Hansen CT; Nielsen L; Münster AM; Abildgaard N
Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297
[TBL] [Abstract][Full Text] [Related]
11. [Multisystemic amyloidosis in 2007].
Grateau G; Valleix S; Callard P
Rev Med Interne; 2007 May; 28(5):281-3. PubMed ID: 17291633
[No Abstract] [Full Text] [Related]
12. Systemic light chain amyloidosis and Sjogren syndrome: an uncommon association.
Perlat A; Decaux O; Gervais R; Rioux N; Grosbois B
Amyloid; 2009; 16(3):181-2. PubMed ID: 19636991
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
[TBL] [Abstract][Full Text] [Related]
14. Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.
Kumar S; Murray D; Dasari S; Milani P; Barnidge D; Madden B; Kourelis T; Arendt B; Merlini G; Ramirez-Alvarado M; Dispenzieri A
Leukemia; 2019 Jan; 33(1):254-257. PubMed ID: 29977017
[No Abstract] [Full Text] [Related]
15. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
16. Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.
Mollee P; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):921-7. PubMed ID: 26812792
[TBL] [Abstract][Full Text] [Related]
17. Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course.
Adami F; Briani C; Binotto G; Altinier S; Tarantini G; Semenzato G
Am J Hematol; 2010 Feb; 85(2):131-2. PubMed ID: 20029992
[No Abstract] [Full Text] [Related]
18. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
19. [AL-amyloidosis and its treatment by eliminating the precursor protein].
Verbeek DE; Hazenberg BP; Jager PL; Kremer Hovinga TK
Ned Tijdschr Geneeskd; 2007 Sep; 151(37):2021-6. PubMed ID: 17929708
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
